These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11807454)

  • 1. Generalized hyperpigmentation with daunorubicin chemotherapy.
    Kroumpouzos G; Travers R; Allan A
    J Am Acad Dermatol; 2002 Feb; 46(2 Suppl Case Reports):S1-3. PubMed ID: 11807454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daunorubicin-induced hyperpigmentation.
    Pol RR; Wright A; Hill A
    Br J Haematol; 2010 Dec; 151(5):414. PubMed ID: 21029070
    [No Abstract]   [Full Text] [Related]  

  • 3. Idarubicin-induced pigmentary changes of the nails.
    Borecky DJ; Stephenson JJ; Keeling JH; Vukelja SJ
    Cutis; 1997 Apr; 59(4):203-4. PubMed ID: 9104543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin.
    Jogi R; Garman M; Pielop J; Orengo I; Hsu S
    J Drugs Dermatol; 2005; 4(5):652-6. PubMed ID: 16167426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia.
    Pinelli A; Mussini C; Bertolini B; Buratti M; Trivulzio S
    Pharmacol Res; 2003 Nov; 48(5):515-8. PubMed ID: 12967599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transverse leukonychia (Mees' lines) due to daunorubicin chemotherapy.
    Shelley WB; Humphrey GB
    Pediatr Dermatol; 1997; 14(2):144-5. PubMed ID: 9144702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
    Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young man with scratches on his back. Bleomycin-related flagellate hyperpigmentation.
    Chen YG; Huang CF; Dai MS
    Ann Emerg Med; 2013 Feb; 61(2):152, 154. PubMed ID: 23331644
    [No Abstract]   [Full Text] [Related]  

  • 9. Bullous acral erythema and concomitant pigmentation on the face and occluded skin.
    Ozkaya-Bayazit E; Diz-Küçükkaya R; Akasya E; Büyükbabani N; Oncü S; Pekçelen Y
    J Eur Acad Dermatol Venereol; 2000 Mar; 14(2):139-40. PubMed ID: 10972102
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous pigmentation after daunorubicin chemotherapy.
    Anderson LL; Thomas DE; Berger TG; Vukelja SJ
    J Am Acad Dermatol; 1992 Feb; 26(2 Pt 1):255-6. PubMed ID: 1552062
    [No Abstract]   [Full Text] [Related]  

  • 11. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
    Hui YF; Cortes JE
    Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daunorubicine in acute myelogenous leukemia in adults.
    Bornstein RS; Theologides A; Kennedy BJ
    JAMA; 1969 Feb; 207(7):1301-6. PubMed ID: 5250070
    [No Abstract]   [Full Text] [Related]  

  • 14. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.
    Fernandez HF; Sun Z; Litzow MR; Luger SM; Paietta E; Racevskis J; Levine RL; Patel JP; Abdel-Wahab O; Ketterling RP; Dewald GW; Bennett JM; Rowe JM; Lazarus HM; Tallman MS
    Haematologica; 2019 Apr; 104(4):e147-e150. PubMed ID: 30467203
    [No Abstract]   [Full Text] [Related]  

  • 16. Minocycline-induced hyperpigmentation in multibacillary leprosy.
    Hu SW; Robinson MR; Newlove T; Meehan S; Levis WR; Patel RR
    Am J Dermatopathol; 2012 Dec; 34(8):e114-8. PubMed ID: 23169418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases.
    Scherschun L; Lee MW; Lim HW
    Arch Dermatol; 2001 Feb; 137(2):179-82. PubMed ID: 11176690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials.
    Su L; Zhu X; Gao S; Li W; Liu X; Tan Y
    J Chemother; 2016 Apr; 28(2):123-8. PubMed ID: 27104964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flagellate pigmentation: a unique adverse effect of bleomycin therapy.
    Al-Khenaizan S; Al-Berouti B
    Eur J Dermatol; 2011; 21(1):146. PubMed ID: 21282096
    [No Abstract]   [Full Text] [Related]  

  • 20. Bleomycin induced hyperpigmentation with yolk sac tumor.
    Yaris N; Cakir M; Kalyoncu M; Okten A
    Indian J Pediatr; 2007 May; 74(5):505-6. PubMed ID: 17526968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.